Clinical study in rural Uganda shows high demand for antiretroviral drugs

July 22, 2012

An ongoing clinical study in rural Uganda, begun in 2011, suggests that many people infected with HIV/AIDS would take antiretroviral drugs if they were available to them—even before they developed symptoms from the disease.

Led by doctors at the University of California, San Francisco (UCSF), the San Francisco General Hospital and Trauma Center (SFGH) and Makerere University School of Medicine in Kampala, , the study is the first to address such attitudes among African who are in the early stages of the disease and not yet sick.

Historically, treatment was initiated only when someone's immune system had declined below a certain threshold, by which point they were sometimes already ill.

Now, mounting evidence suggests that providing antiretroviral to people long before they get sick can be a direct benefit to both them and society—by keeping the individual healthy, and by reducing the transmission of within communities.

Even so, scientists have known little about patients' attitudes towards taking antiretroviral therapy in the early stages of HIV disease. "Given that there are millions of people in Africa taking and millions more in need of them, there is surprisingly little data on patients' attitudes in this part of the world toward the therapy itself," said Moses Kamya, a professor and chair of the Department of Medicine at Makerere University.

The new clinical study addressed these questions directly. Its first results will be revealed at the XIX International Conference in Washington, D.C. on Sunday, July 22, 2012.

"There was very high interest among the people eligible for this study in taking antiretrovirals," said Vivek Jain, MD, MAS, assistant professor of medicine in the UCSF Division of HIV/AIDS at SFGH.

In the study, 188 patients with HIV were enrolled and offered antiretroviral drugs. All had a high CD4+ T cell count (>350)—the classic measure of the immune system's robustness and an indication of being in the early stages of disease, before a decline towards AIDS.

Almost all of the patients—186 of 188—elected to take the treatment. Ninety percent identified the main reason why they wanted to start therapy as their desire to stay healthy, 52 percent cited a desire to continue working and an equal 52 percent cited a desire to continue caring for their families. Other leading reasons patients wanted to take therapy centered around their desire not to transmit HIV to partners and future children.

The poster, "Patient attitudes toward HIV antiretroviral therapy initiation at high CD4+ cell counts" by Vivek Jain, Dathan Byonanebye, Jemimah Muhaawe, Jane Kabami, Doug Black, Tamara Clark, Gabriel Chamie, Elvin Geng, James Rooney, Edwin Charlebois, Gideon Amanyire, Diane Havlir, Moses Kamya, and the SEARCH Collaboration will be unveiled at 3:00 p.m. ET on Sunday, July 22, 2012.

Explore further: HIV rate in SF could be cut sharply with expanded treatment, study predicts

More information: pag.aids2012.org/abstracts.aspx?aid=5458

Related Stories

HIV rate in SF could be cut sharply with expanded treatment, study predicts

April 13, 2011
If HIV-infected adults in San Francisco began taking antiretroviral treatments as soon as they were diagnosed, the rate of new HIV infections among men who have sex with men would be cut by almost 6o percent over five years, ...

New study adds further guidance on when to start antiretroviral therapy for HIV

September 26, 2011
One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment.

Only one-third of HIV-positive patients remain in care before starting treatment

July 19, 2011
In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return ...

Blood cell test for HIV treatment monitoring is cheaper but just as effective

December 1, 2011
(Medical Xpress) -- A cheaper laboratory test that helps guide anti-retroviral drug treatment for people with HIV/AIDS may be just as effective as a more sophisticated test, a group of international researchers has found ...

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.